Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.

[1]  G. Wahl,et al.  DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. , 1994, Genes & development.

[2]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[3]  Y Taya,et al.  Enhanced phosphorylation of p53 by ATM in response to DNA damage. , 1998, Science.

[4]  Y Taya,et al.  Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. , 1998, Science.

[5]  Yoichi Taya,et al.  ATM associates with and phosphorylates p53: mapping the region of interaction , 1999, Nature Genetics.

[6]  Taeil Kim,et al.  Activation of Interferon Regulatory Factor 3 in Response to DNA-damaging Agents* , 1999, The Journal of Biological Chemistry.

[7]  Y Taya,et al.  A role for ATR in the DNA damage-induced phosphorylation of p53. , 1999, Genes & development.

[8]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[9]  H. Piwnica-Worms,et al.  ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1 , 2001, Molecular and Cellular Biology.

[10]  Linda Hicke,et al.  Ubiquitin and proteasomes: Protein regulation by monoubiquitin , 2001, Nature Reviews Molecular Cell Biology.

[11]  K. Khanna,et al.  DNA double-strand breaks: signaling, repair and the cancer connection , 2001, Nature Genetics.

[12]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[13]  M. Somerville.  A postmodern moral tale: the ethics of research relationships , 2002, Nature Reviews Drug Discovery.

[14]  L. Cantley,et al.  Interferon regulatory factor-3 is an in vivo target of DNA-PK , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[16]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[17]  J. Bartek,et al.  Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent Phosphorylation of Chk1 on Ser-317 in Response to Ionizing Radiation* , 2003, The Journal of Biological Chemistry.

[18]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[19]  J. Brown,et al.  Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.

[20]  Ji-Hoon Lee,et al.  ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex , 2005, Science.

[21]  B. Kaina,et al.  DNA damage-induced cell death by apoptosis. , 2006, Trends in molecular medicine.

[22]  Gary Walsh,et al.  Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.

[23]  Jiri Bartek,et al.  ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks , 2006, Nature Cell Biology.

[24]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.

[25]  Georgios Giamas,et al.  Protein kinases as targets for cancer treatment. , 2007, Pharmacogenomics.

[26]  P. Murray.  The JAK-STAT Signaling Pathway: Input and Output Integration1 , 2007, The Journal of Immunology.

[27]  N. Reich,et al.  IRF-3-dependent and augmented target genes during viral infection , 2008, Genes and Immunity.

[28]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[29]  E. May,et al.  Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents , 2008, Cell Death and Differentiation.

[30]  George A. Calin,et al.  MicroRNAs — the micro steering wheel of tumour metastases , 2009, Nature Reviews Cancer.

[31]  I. Melero,et al.  Lysine 63 Polyubiquitination in Immunotherapy and in Cancer-promoting Inflammation , 2009, Clinical Cancer Research.

[32]  J. Bartek,et al.  The DNA-damage response in human biology and disease , 2009, Nature.

[33]  M. Karin.  NF-kappaB as a critical link between inflammation and cancer. , 2009, Cold Spring Harbor perspectives in biology.

[34]  R. Knight,et al.  STAT3 modulates the DNA damage response pathway , 2010, International journal of experimental pathology.

[35]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[36]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[37]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[38]  Kavya Rakhra,et al.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. , 2010, Cancer cell.

[39]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[40]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[41]  P. Li,et al.  IRF8 and IRF3 cooperatively regulate rapid interferon-β induction in human blood monocytes. , 2011, Blood.

[42]  G. Semenza,et al.  Hypoxia-Inducible Factors in Physiology and Medicine , 2012, Cell.

[43]  A. Giobbie-Hurder,et al.  The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition , 2012, Clinical Cancer Research.

[44]  Jungbin Kim,et al.  DNA damage induces the IL-6/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors. , 2012, Cancer letters.

[45]  H. Ren,et al.  DNA-PK is a DNA sensor for IRF-3-dependent innate immunity , 2012, eLife.

[46]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[47]  Travis J Cohoon,et al.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. , 2013, Cancer discovery.

[48]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.

[49]  Cuiping Liu,et al.  A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma , 2013, Human Genetics.

[50]  David M. Thomas,et al.  The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.

[51]  R. Gascoyne,et al.  Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. , 2013, Blood.

[52]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[53]  Jinfang Zhang,et al.  Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. , 2014, Biochimica et biophysica acta.

[54]  Antoni Ribas,et al.  Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma , 2014, Clinical Cancer Research.

[55]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[56]  Lixia Diao,et al.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.

[57]  C. Graham,et al.  A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. , 2014, Cancer research.

[58]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[59]  S. Tangye,et al.  STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation , 2014, Proceedings of the National Academy of Sciences.

[60]  J. Taube,et al.  Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.

[61]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[62]  Shohei Koyama,et al.  Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. , 2014, Cancer cell.

[63]  M. McKeown,et al.  Therapeutic strategies to inhibit MYC. , 2014, Cold Spring Harbor perspectives in medicine.

[64]  Bin Zhao,et al.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer , 2015, Cell.

[65]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[66]  N. Matsumura,et al.  IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer , 2015, British Journal of Cancer.

[67]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[68]  J. Allison.  Immune Checkpoint Blockade in Cancer Therapy: The 2015 Lasker-DeBakey Clinical Medical Research Award. , 2015, JAMA.

[69]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[70]  N. Grishin,et al.  Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation , 2015, Science.

[71]  S. Pinho,et al.  Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.

[72]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[73]  Razelle Kurzrock,et al.  PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.

[74]  S. Murphy,et al.  Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. , 2015, Cancer research.

[75]  G. Freeman,et al.  Combination cancer immunotherapy and new immunomodulatory targets , 2015, Nature Reviews Drug Discovery.

[76]  K. Ishii,et al.  Genome-derived cytosolic DNA mediates type I interferon-dependent rejection of B cell lymphoma cells. , 2015, Cell reports.

[77]  M. O’Connor,et al.  Targeting the DNA Damage Response in Cancer. , 2015, Molecular cell.

[78]  I. Melero,et al.  Evolving synergistic combinations of targeted immunotherapies to combat cancer , 2015, Nature Reviews Cancer.

[79]  Jian Dong,et al.  STAT3 regulated ATR via microRNA-383 to control DNA damage to affect apoptosis in A431 cells. , 2015, Cellular signalling.

[80]  Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. , 2015, Cell.

[81]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[82]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[83]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[84]  E. E. Vincent,et al.  The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. , 2015, Immunity.

[85]  David M. Woods,et al.  HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade , 2015, Cancer Immunology Research.

[86]  X. Chen,et al.  Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. , 2015, Cellular signalling.

[87]  Lauren L. Ritterhouse,et al.  Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. , 2015, JAMA oncology.

[88]  A. Ribas,et al.  What does PD-L1 positive or negative mean? , 2016, The Journal of experimental medicine.

[89]  G. Calin,et al.  PDL1 Regulation by p53 via miR-34 , 2015, Journal of the National Cancer Institute.

[90]  Y. Natkunam,et al.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  G. Hortobagyi,et al.  Deubiquitination and Stabilization of PD-L1 by CSN5. , 2016, Cancer cell.

[92]  Satoru Miyano,et al.  Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers , 2016, Nature.

[93]  N. Hacohen,et al.  Neoantigens encoded in the cancer genome. , 2016, Current opinion in immunology.

[94]  Ping Wang,et al.  miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint , 2016, Nature Communications.

[95]  S. Baum,et al.  Role of Genomic Instability in Immunotherapy with Checkpoint Inhibitors. , 2016, Anticancer research.

[96]  Deborah S. Barkauskas,et al.  Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity , 2016, Science.

[97]  A. Redig,et al.  Targeting BET bromodomain proteins in solid tumors , 2016, Oncotarget.

[98]  Lauren L. Ritterhouse,et al.  Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer , 2016, Oncotarget.

[99]  C. Jiang,et al.  Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  G. López-Castejón,et al.  Deubiquitinases: Novel Therapeutic Targets in Immune Surveillance? , 2016, Mediators of inflammation.

[101]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[102]  N. Zhang,et al.  The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. , 2016, International journal of oncology.

[103]  E. Wherry,et al.  Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling , 2016, Cell.

[104]  P. Patel,et al.  Glycosylation: a hallmark of cancer? , 2016, Glycoconjugate Journal.

[105]  K. Okkenhaug,et al.  Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. , 2016, Cancer discovery.

[106]  S. Varambally,et al.  Genomic and Epigenomic Alterations in Cancer. , 2016, The American journal of pathology.

[107]  Matthew V. Holt,et al.  The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity , 2016, Cell.

[108]  N. Rizvi,et al.  PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? , 2016, Journal of Immunotherapy for Cancer.

[109]  Jun Yao,et al.  Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity , 2016, Nature Communications.

[110]  C. Qian,et al.  Post-Translational Modification Control of Innate Immunity. , 2016, Immunity.

[111]  C. Petosa,et al.  Bromodomains: Structure, function and pharmacology of inhibition. , 2016, Biochemical pharmacology.

[112]  N. Matsumura,et al.  Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity , 2016, Clinical Cancer Research.

[113]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[114]  Wen-Qi Jiang,et al.  PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma , 2016, Journal of Hematology & Oncology.

[115]  Benjamin G. Bitler,et al.  BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. , 2016, Cell reports.

[116]  G. Freeman,et al.  Coinhibitory Pathways in Immunotherapy for Cancer. , 2016, Annual review of immunology.

[117]  Robert R Yauch,et al.  Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice , 2017, Nature Communications.

[118]  F. Slack,et al.  MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs , 2017, Leukemia.

[119]  D. Grandér,et al.  PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma , 2017, Leukemia.

[120]  M. Shipp,et al.  Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. , 2017, Blood.

[121]  G. Hortobagyi,et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.

[122]  Tiara Bunga Mayang Permata,et al.  DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells , 2017, Nature Communications.

[123]  Sang Yeon Cho,et al.  Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. , 2017, Biochemical and biophysical research communications.

[124]  Freeman,et al.  PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity , 2017, The Journal of experimental medicine.

[125]  Sudha Rao,et al.  Epigenetics and immunotherapy: The current state of play , 2017, Molecular immunology.

[126]  Zhenyi Xue,et al.  miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. , 2017, Biochemical and biophysical research communications.

[127]  C. Zahnow,et al.  Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer , 2017, Cell.

[128]  M. Ellis,et al.  CDK4/6 inhibition triggers anti-tumor immunity , 2017, Nature.

[129]  H. Horlings,et al.  Identification of CMTM6 and CMTM4 as PD-L1 protein regulators , 2017, Nature.

[130]  Zhijian J. Chen,et al.  cGAS is essential for the antitumor effect of immune checkpoint blockade , 2017, Proceedings of the National Academy of Sciences.

[131]  Y. Chang,et al.  MYC expression correlates with PD-L1 expression in non-small cell lung cancer. , 2017, Lung cancer.

[132]  S. Staibano,et al.  A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma , 2017, Oncotarget.

[133]  S. Dawson,et al.  CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity , 2017, Nature.

[134]  S. Chouaib,et al.  Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer , 2017, Oncogene.

[135]  H. Zeng.  mTOR signaling in immune cells and its implications for cancer immunotherapy. , 2017, Cancer letters.

[136]  Robert Damoiseaux,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.

[137]  D. Komander,et al.  Mechanisms of Deubiquitinase Specificity and Regulation. , 2017, Annual review of biochemistry.

[138]  K. Tao,et al.  MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma , 2017, Oncotarget.

[139]  H. Horita,et al.  Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton , 2017, Neoplasia.

[140]  L. Cerulo,et al.  Emerging Insight into MAPK Inhibitors and Immunotherapy in Colorectal Cancer. , 2017, Current Medicinal Chemistry.

[141]  R. Shaw,et al.  AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance. , 2017, Molecular cell.

[142]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[143]  Huidong Shi,et al.  The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion , 2017, Journal of the National Cancer Institute.

[144]  Christopher J. Ott,et al.  BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1 , 2017, Cell reports.

[145]  Jeff D. Thomas,et al.  Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1 , 2017, Molecular Cancer Research.

[146]  T. Waldmann,et al.  Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. , 2017, Annual review of immunology.

[147]  Michael S. Goldberg,et al.  DNA Damage and Repair Biomarkers of Immunotherapy Response. , 2017, Cancer discovery.

[148]  M. Salto‐Tellez,et al.  Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer , 2016, Journal of the National Cancer Institute.

[149]  Kwok-Kin Wong,et al.  MUC1-C INTEGRATES PD-L1 INDUCTION WITH REPRESSION OF IMMUNE EFFECTORS IN NON-SMALL CELL LUNG CANCER , 2017, Oncogene.

[150]  Libin Guo,et al.  The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint , 2017, International journal of molecular sciences.

[151]  George Wu,et al.  Emerging role of DUBs in tumor metastasis and apoptosis: Therapeutic implication , 2017, Pharmacology & therapeutics.

[152]  T. Schumacher,et al.  Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.

[153]  C. Zahnow,et al.  Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells , 2018, Proceedings of the National Academy of Sciences.

[154]  G. Freeman,et al.  LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade , 2018, Cell.

[155]  Jun Yao,et al.  Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. , 2018, Cancer cell.

[156]  S. Koide,et al.  Next-generation antibodies for post-translational modifications. , 2018, Current opinion in structural biology.

[157]  Juanita Lopez,et al.  Combining DNA damaging therapeutics with immunotherapy: more haste, less speed , 2017, British Journal of Cancer.

[158]  S. Sigismund,et al.  Emerging functions of the EGFR in cancer , 2017, Molecular oncology.

[159]  G. Rabinovich,et al.  Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer. , 2018, Cancer cell.

[160]  G. Freeman,et al.  Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance , 2017, Nature.

[161]  P. Khanal,et al.  The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1. , 2018, Cancer research.

[162]  K. Mouw,et al.  From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation , 2018, British Journal of Cancer.

[163]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[164]  Mark W. Ball,et al.  Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma , 2018, Science.

[165]  M. Hung,et al.  STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion , 2018, Nature Communications.

[166]  W. Symmans,et al.  Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. , 2018, Molecular cell.

[167]  Yoshiyuki Suzuki,et al.  PD‐L1 expression is mainly regulated by interferon gamma associated with JAK‐STAT pathway in gastric cancer , 2017, Cancer science.

[168]  Henry W. Long,et al.  A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing , 2018, Science.

[169]  M. Karin,et al.  NF-κB, inflammation, immunity and cancer: coming of age , 2018, Nature Reviews Immunology.

[170]  Tae Kon Kim,et al.  Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. , 2018, Trends in immunology.

[171]  J. Soria,et al.  Epigenetic modifiers as new immunomodulatory therapies in solid tumours , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[172]  E. Shin,et al.  YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma , 2018, Cancer Immunology Research.